About Genomics
Genomics is a Healthcare company based in Oxford (United Kingdom) founded in 2014 by Gil McVean and Peter Donnelly. Genomic risk assessment and prevention platform is provided. It operates on a AI-as-a-Service, Professional Services, and HealthTech model. Genomics has raised $115.54 million across 10 funding rounds from investors including Vertex Pharmaceuticals, HHS and University of Oxford. Its chief executive, as recorded, is Peter Donnelly. Its website genomics.com draws about 16 thousand monthly visits. Genomics offers products and services including Health Insights, Drug Discovery Platform, and Precision Health Tools. Its focus areas include Biotechnology and Genomics. Its legal entity is Genomics Ltd.
Company details
Genomics is engaged in harnessing genetic data to improve population health and accelerate drug discovery. Solutions are provided for healthcare providers, employers, life sciences, and partners through predictive genomics and personalized health insights. The company operates in the biotechnology sector, focusing on disease risk prediction and precision health delivery. Collaborations are maintained with global pharmaceutical companies and research institutions to develop innovative treatments and screening methods.
- Headquarters Oxford, United Kingdom
- Founders Gil McVean, Peter Donnelly
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website genomics.com
- Social LinkedIn X
- Legal Name Genomics Ltd.
- Total Equity Funding$115.54M (USD)
in 10 rounds
- Latest Funding Round$44.51M (USD), Series C
Jan 2024
- InvestorsVertex Pharmaceuticals
& 13 more
Products & Services of Genomics
Genomics offers a comprehensive portfolio of products and services, including Health Insights, Drug Discovery Platform, and Precision Health Tools.
Personalized health insights are provided through genomic analysis.
Drug discovery is accelerated using population-scale genetic data.
Precision health delivery is enabled through genetic stratification.
Funding Insights of Genomics
Genomics has successfully raised a total of $115.54M across 10 strategic funding rounds. The most recent funding activity was a Series C round of $44.51 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $115.54M
- Total Rounds 10
- Last Round Series C — $44.51M
- First Round $204,960
(Apr 2014)
- Investors Count 14
All 10 funding rounds of Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $44.51M | Series C | – | F-Prime Capital | |
| Dec 2018 | $10.1M | Series B | – | Foresite Capital | |
| Aug 2018 | $32.32M | Series B | – | Vertex Pharmaceuticals | |
| Feb 2016 | $5.57M | Grant | – | – | |
| Mar 2015 | $3M | Grant | – | – | – |
| Nov 2014 | $28.6M | Series B | – | IP Group | |
| Sep 2014 | $599,686 | Grant | – | – | |
| Aug 2014 | $1.85M | Grant | – | – | |
| May 2014 | $4.06M | Grant | – | – | |
| Apr 2014 | $204,960 | Grant | – | – |
14 investors in total: 14 institutional.
Investors in Genomics
Genomics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Vertex Pharmaceuticals, HHS and University of Oxford.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Corporate-backed venture capital fund | massmutualventures.com | Boston, United States | ||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Venture capital and advisory services are offered across multiple sectors. | 2001 | ipgroupplc.com | London, United Kingdom | |
Investment management services for science ventures are provided in Oxford. | oxfordscienceenterprises.com | Oxford, United Kingdom | ||
Tanarra is recognized as an Asia Pacific alternative asset investment firm. | tanarra.com | Australia | ||
Independent firm allocating capital to global ideas for superior investor returns. | 2019 | infinityinvestmentpartners.com | London, United Kingdom | |
Developer of drugs for the treatment of multiple disorders | 1989 | vrtx.com | United States | |
Diversified investment portfolios are managed for clients by the firm. | 2014 | woodfordfunds.com | Swindon, United Kingdom | |
Offers fundamental equity investing and management for institutional clients since 1998. | 1998 | lansdownepartners.com | London, United Kingdom |
Investor details for Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genomics
2 people are tracked at Genomics (2 in leadership).
| Name | Role | Group |
|---|---|---|
Gil McVean | Co Founder & Director | Leadership |
Peter Donnelly | Co-Founder & CEO | Leadership |
Complete people profiles for Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Genomics
3 dated milestones of Genomics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Genomics is founded.
- Funding First funding round of $205K.
- Funding Latest funding round, Series C, of $44.5M.
Web traffic of Genomics
The website of Genomics (genomics.com) receives about 16.4K visits a month.
- Monthly visits16.4K
▼ 28.8% vs previous month
Websites whose visitors overlap most with Genomics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| gilead.com | 100% | 576.5K | #103,109 | View details | |
| evoxtherapeutics.com | 72% | 9K | #2,464,657 | View details | |
| oxb.com | 60% | 21.1K | #1,726,571 | View details | |
| ultimagenomics.com | 60% | 12.9K | #2,282,855 | View details | |
| fabricgenomics.com | 60% | 3.5K | #5,656,833 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Genomics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as Genomics (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genomics
Complete news archive for Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genomics
Genomics was founded in 2014.
Genomics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Peter Donnelly is the CEO of Genomics, as recorded in our data. They have also founded this company.
Genomics is a funded company, having raised a total of $115.54M across 10 funding rounds to date. The company's 1st funding round was a Grant of $204.96K, raised on Apr 2014.
Genomics is engaged in harnessing genetic data to improve population health and accelerate drug discovery. Solutions are provided for healthcare providers, employers, life sciences, and partners through predictive genomics and personalized health insights. The company operates in the biotechnology sector, focusing on disease risk prediction and precision health delivery. Collaborations are maintained with global pharmaceutical companies and research institutions to develop innovative treatments and screening methods.
Genomics offers Health Insights, Drug Discovery Platform, and Precision Health Tools.
Genomics has 14 investors. Key investors include Vertex Pharmaceuticals, HHS, University of Oxford, IP Group, and Invesco Mutual Fund.
Genomics operates through Genomics Ltd..